NEW YORK (GenomeWeb News) – InforSense today said that it has "developed a long-term relationship" with Celera, under which the molecular diagnostics firm is using InforSense's Translational Research Solution in automating experimental data analysis and molecular annotation.

London-based InforSense said that it has provided Celera with a translation research platform that will support clinical data browsing, automated integration and analysis of enzyme-linked immunoassays, single nucleotide polymorphisms, and other experimental and public data.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.